Second line therapies for the treatment of gastrointestinal stromal tumor

Current Opinion in Oncology

Volumn 19, Issue 4, 2007, Pages 353-358

  Joensuu, Heikki ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Gastrointestinal stromal tumor; GIST; Imatinib; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

17 ALLYLAMINO 18 DEMETHOXYGELDANAMYCIN; 4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; ANTINEOPLASTIC AGENT; CGP 74588; CISPLATIN; DASATINIB; ENZYME INDUCING AGENT; ENZYME INDUCING ANTIEPILEPTIC DRUG; EVEROLIMUS; FLAVOPIRIDOL; GELFOAM; IMATINIB; IPI 504; MIDOSTAURIN; NILOTINIB; OBLIMERSEN; POLYVINYL ALCOHOL; SORAFENIB; STEM CELL FACTOR; SUNITINIB; UNCLASSIFIED DRUG; VATALANIB;

ARTIFICIAL EMBOLISM; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXON; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HEPATIC ARTERY; HUMAN; HYPOTHYROIDISM; LETHARGY; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; SURGICAL TECHNIQUE; THYROID DISEASE; THYROID FUNCTION; TREATMENT FAILURE;

GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES; TREATMENT FAILURE;

EID: 34249997788     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3281338885     Document Type: Review

References (30)

1. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 2005; 103:821-829.
2. Agaimy A, Wunsch PH, Hostaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007; 31:113-120. This highly interesting study reported the presence of many microscopic GISTs in the stomachs of adults representing the general population. Many microscopic GISTs contained KITmutation. Similar findings have been reported by Kawanowa et al. (Hum Pathol 2006; 37:1527-1535).
3. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24:4764-4774. This report contains a summary of secondary mutations found in GISTs treated with imatinib.
4. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42:1093-1103. A large series addressing the predictive value of KIT and PDGFRA mutations on response to imatinib administered at either 400 mg or 800mg per day.
5. Linton KM, Taylor MB, Radford JA. Response evaluation in gastrointestinal stromal tumors treated with imatinib:misdiagnosis of liver progression onCT due to cystic change in liver metastases. Br J Radiol 2006; 79:e40-e44.
6. Agaimy A, Wunsch PH, Sobin LH, et al. Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol 2006; 23:120-129.
7. Shankar S, vanSonnenberg E, Deasi J, et al. Gastrointestinal stromal tumor: New nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 2005; 235:892-898.
8. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400 mg. Eur J Cancer 2005; 41: 1751-1757.
9. Wen PY, Young WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant liomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006; 12:4899-4907.
10. Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24:2325-2331.
11. Hartmann JT, Heidel F, Stoehlmacher J, et al. Pattern of progression and its impact on outcome in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: A retrospective multicenter long-term follow-up study [abstract]. J Clin Oncol 2006; 24:530s.
12. Nishida T, Hasegawa J, Nishitani A, et al. Surgical interventions for focal progression of gastrointestinal stromal tumors under imatinib therapy [abstract]. J Clin Oncol 2006; 24:531s.
13. Ikezoe T, Yang Y, Nishioka C, et al. Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: Enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling. Cancer Sci 2006; 97: 945-951.
14. Prenen H, Cools J, Mentens N, et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006; 12:2622-2627.
15. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368:1329-1338. This pivotal trial compared sumitinib malate with placebo in GIST patients who were either intolerant to imatinib or whose disease progressed while on imatinib therapy. The largest ever conducted study to evaluate systemic second-line therapies in GIST. Median time to tumor progression was 27.3 weeks in patients receiving sunitinib and 6.4 weeks in those on placebo.
16. Bono P, Krause A, Blanke CD, et al. Serum KIT, SCF and VEGF levels in gastrointestinal tumor patients treated with imatinib. Blood 2004; 103:2929-2935.
17. Heinrich MC, Maki RG, Corless CL, et al. Sunitinib response in imatinibresistant GIST correlates with KIT and PDGFRA mutation status [abstract]. J Clin Oncol 2006; 24:520s.
18. Desai J, Yassa L, Marqusee S, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006; 145:660-664. This important study demonstrated frequent abnormalities in the thyroid function and clinical hypothyroidism in GIST patients treated with sunitinib. Some patients developed destructive thyroiditis through follicular cell apoptosis.
19. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007; 99:81-83. This study found a high frequency of thyroid function abnormalities in patients treated with sunitinib for renal cell cancer.
20. Kobayashi K, Gupta S, Trent JC, et al. Hepatic artery chemoembolozation for 110 gastrointestinal stromal tumors. Cancer 2006; 107:2833-2841. This is probably the largest single-center series on hepatic artery chemoembolization in GIST published to date. The data suggest that many GIST patients with metastases in the liver may benefit from chemoembolization.
21. Maluccio MA, Covey AM, Schubert J, et al. Treatment of metastatic sarcoma to the liver with bland embolization. Cancer 2006; 107:1617-1623.
22. van Oosterom A, Reichardt P, Blay J-Y, et al. A phase I/II trial of the oral mTOR inhibitor everolimus and imatinib in patients with gastrointestinal stromal tumor refractory to imatinib:study uptate [abstract]. J Clin Oncol 2005; 23:824s.
23. Joensuu H, De Braud F, Coco P, et al. A phase II, open-label study of PTK787/ ZK222584 in the treatment of metastatic gastrointestinal stromal tumors (GISTs) resistant to imatinib mesylate [abstract]. Proc Am Soc Clin Oncol 2006; 24:527s.
24. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005; 128:270-279.
25. Reichardt P, Pink D, Linder T, et al. A phase I/II trial of the oral PKC-inhibitor PKC416 in combination with imatinib mesylate in patients with gastrointestinal stromal tumor (GIST) refractory to imatinib [abstract]. J Clin Oncol 2005; 23:196s.
26. Van Den Abbeele AD, Barnes AS, De Vries JD, et al. Assessment of response using FGD-PET and CT in a phase I study of AMN107 alone or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST) [abstract]. J Clin Oncol 2006; 24:142s.
27. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66:473-481.
28. Evans TRJ, Morgan JA, van den Abbeele AD, et al. Phase I dose-escalation study of the SRC and multikinase inhibitor BMS-354825 in patients with GIST and other solid tumors [abstract]. J Clin Oncol 2005; 23:200s.
29. Bauer S, Yu LK, Demetri GD, Fletcher JA. Heat shock mprotein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006; 66:9153-9161.
30. Sambol EB, Ambrosini G, Geha RC, et al. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells. Cancer Res 2006; 66:5858-5866.